Literature DB >> 11709453

Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale.

A J Geirsson1, F A Wollheim, A Akesson.   

Abstract

OBJECTIVE: To assess organ involvement according to a modified Medsger severity scale and its relation to outcome and prognosis in patients with systemic sclerosis.
METHODS: One hundred consecutive patients observed in Lund with systemic sclerosis were followed up for a period of 14 years. The mean follow up time was 7.7 years. Initial assessment and an annual evaluation was performed for each patient, with a mean visit frequency of 5.6 per patient.
RESULTS: Age at referral, high total skin score, truncal skin involvement, low vital capacity, low static lung compliance, low Cr-EDTA clearance, and ECG abnormalities at the initial assessment predict poor outcome. A severity scoring system for five organ systems indicates a slow progression of organ dysfunction after recruitment into the study. The female: male ratio was 2:1, the mean age at onset of symptoms was 42.3 (range 3-82), and the mean age at recruitment was 47.2 years (range 17-82). Thirty patients died during the follow up period at the mean age of 61.3 years (range 33-85). The causes of death were directly related to systemic sclerosis in at least 10 patients, infections in six, cancers in nine, and other causes in four patients. The standardised mortality ratio was 3.5 and 3.7 for men and women, respectively.
CONCLUSION: A high severity score for function of vital organs was shown to predict shortened survival. In this study a severity score based on simple clinical assessment variables was able to predict poor outcome from extensive skin changes, ECG changes, and compromised lung and renal function. Organ dysfunction mainly became manifest during the first five years of the disease, whereafter organ function remained largely stable.

Entities:  

Mesh:

Year:  2001        PMID: 11709453      PMCID: PMC1753441          DOI: 10.1136/ard.60.12.1117

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

1.  Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. A study of 271 cases.

Authors:  R G FARMER; R W GIFFORD; E A HINES
Journal:  Circulation       Date:  1960-06       Impact factor: 29.690

2.  Survival in scleroderma.

Authors:  R Bennett; R Bluestone; P J Holt; E G Bywaters
Journal:  Ann Rheum Dis       Date:  1971-11       Impact factor: 19.103

3.  A method for determination of pulmonary elastic recoil and resistance at a regulated flow rate.

Authors:  B Jonson
Journal:  Scand J Clin Lab Invest       Date:  1969-09       Impact factor: 1.713

4.  Factors predicting development of renal involvement in progressive systemic sclerosis.

Authors:  V D Steen; T A Medsger; T A Osial; G L Ziegler; A P Shapiro; G P Rodnan
Journal:  Am J Med       Date:  1984-05       Impact factor: 4.965

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma.

Authors:  W P Follansbee; E I Curtiss; T A Medsger; V D Steen; B F Uretsky; G R Owens; G P Rodnan
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

7.  Ultrasound examination of skin thickness in patients with progressive systemic sclerosis (scleroderma).

Authors:  A Akesson; L Forsberg; E Hederström; F Wollheim
Journal:  Acta Radiol Diagn (Stockh)       Date:  1986 Jan-Feb

8.  Use of the triolein breath test for the demonstration of fat malabsorption in coeliac disease.

Authors:  B Akesson; C H Florén
Journal:  Scand J Gastroenterol       Date:  1984-05       Impact factor: 2.423

9.  Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients.

Authors:  T A Medsger; A T Masi; G P Rodnan; T G Benedek; H Robinson
Journal:  Ann Intern Med       Date:  1971-09       Impact factor: 25.391

10.  Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis.

Authors:  A Kahan; J Y Devaux; B Amor; C J Menkès; S Weber; A Nitenberg; A Venot; F Guérin; M Degeorges; J C Roucayrol
Journal:  N Engl J Med       Date:  1986-05-29       Impact factor: 91.245

View more
  11 in total

1.  Assessment of nailfold capillaries with a handheld dermatoscope may discriminate the extent of organ involvement in patients with systemic sclerosis.

Authors:  Juan C Arana-Ruiz; Luis H Silveira; Diana Castillo-Martínez; Luis M Amezcua-Guerra
Journal:  Clin Rheumatol       Date:  2015-11-11       Impact factor: 2.980

2.  Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.

Authors:  C Rigamonti; L M Shand; M Feudjo; C C Bunn; C M Black; C P Denton; A K Burroughs
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

3.  Gender differences in clinical features and outcomes of a Portuguese systemic sclerosis cohort.

Authors:  Raquel Freitas; Patrícia Martins; Eduardo Dourado; Tânia Santiago; Francisca Guimarães; Bruno Miguel Fernandes; Salomé Garcia; Beatriz Samões; Ana Sofia Pinto; Nuno Gonçalves; Maria Helena Lourenco; Emanuel Costa; Margarida Rocha; Maura Couto; Ana Catarina Duarte; Filipe Araújo; Inês Cordeiro; Fátima Godinho; Catarina Resende; Maria João Salvador; Ana Cordeiro; Maria José Santos
Journal:  Clin Rheumatol       Date:  2021-11-20       Impact factor: 2.980

Review 4.  A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.

Authors:  Maria-Grazia Lazzaroni; Silvia Piantoni; Fabrizio Angeli; Stefania Bertocchi; Franco Franceschini; Paolo Airò
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-07       Impact factor: 10.817

5.  Ultrasound assessment of ex vivo lung tissue properties using a fluid-filled negative pressure bath.

Authors:  Sarah Duenwald-Kuehl; Melissa L Bates; Sonia Y Cortes; Marlowe W Eldridge; Ray Vanderby
Journal:  J Biomech Eng       Date:  2014-07       Impact factor: 2.097

6.  What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).

Authors:  Xiangning Fan; Janet Pope; Murray Baron
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

7.  Mortality in systemic sclerosis-a single centre study from the UK.

Authors:  Gemma Strickland; John Pauling; Charlotte Cavill; Gavin Shaddick; Neil McHugh
Journal:  Clin Rheumatol       Date:  2013-06-29       Impact factor: 2.980

8.  Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.

Authors:  Charlie Strange; Marcy B Bolster; Michael D Roth; Richard M Silver; Arthur Theodore; Jonathan Goldin; Philip Clements; Joanie Chung; Robert M Elashoff; Robert Suh; Edwin A Smith; Daniel E Furst; Donald P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

9.  Measurement of Serum Klotho in Systemic Sclerosis.

Authors:  Rossella Talotta; Sara Bongiovanni; Teresa Letizia; Federica Rigamonti; Maria Chiara Ditto; Fabiola Atzeni; Fausto Salaffi; Alberto Batticciotto; Maria Chiara Gerardi; Marco Antivalle; Tarcisio Vago; Maurizio Benucci; Piercarlo Sarzi-Puttini
Journal:  Dis Markers       Date:  2017-08-22       Impact factor: 3.434

10.  Preliminary study of cardiovascular manifestations and cardiac severity scale in 58 patients with systemic sclerosis in iran using the medsger scale.

Authors:  Hadi Poormoghim; Mohamad Ali Poorkarim; Maziar Moradi Lakeh; Behnaz Nozary Heshmati; Simin Almasi; Mojtaba Hakim
Journal:  J Tehran Heart Cent       Date:  2010-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.